Cargando…
Cardiovascular, renal and liver events associated with human immunodeficiency virus type 1 infection and antiretroviral therapy
The first 15 years of the human immunodeficiency virus type 1 epidemic was characterized by patients progressing to clinical acquired immunodeficiency syndrome and death. The availability of potent antiretrovirals led to the recognition of unique adverse events associated with select drugs. More rec...
Autor principal: | Daar, Eric S |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Medicine Reports Ltd
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2924718/ https://www.ncbi.nlm.nih.gov/pubmed/20948738 http://dx.doi.org/10.3410/M1-43 |
Ejemplares similares
-
Impact of Integrase Inhibitors on Cardiovascular Disease Events in People With Human Immunodeficiency Virus Starting Antiretroviral Therapy
por: Surial, Bernard, et al.
Publicado: (2023) -
START or SMART? Timing of Antiretroviral Therapy Initiation and Cardiovascular Risk for People With Human Immunodeficiency Virus Infection
por: Siedner, Mark J.
Publicado: (2016) -
Metabolic syndrome and cardiovascular disease risk assessment among human immunodeficiency virus-infected individuals on antiretroviral therapy
por: Idiculla, Jyothi, et al.
Publicado: (2018) -
Metabolic syndrome and cardiovascular disease risk assessment among human immunodeficiency virus-infected individuals on antiretroviral therapy
por: Al-Mendalawi, Mahmood Dhahir
Publicado: (2019) -
Factors Associated With Liver Steatosis in People With Human Immunodeficiency Virus on Contemporary Antiretroviral Therapy
por: Riebensahm, Carlotta, et al.
Publicado: (2022)